OMV & Exosome Boosted CAR-T Development Services

Q: Q2: How does this platform affect the risk of CRS?

A2: Unlike live T cell therapies that undergo rapid in vivo expansion and activation-induced cytokine bursts, our exosome-based approach is cell-free and biologically contained. As a result, the potential for triggering severe CRS is extremely low, offering a substantially improved safety profile for clinical applications.

Online Inquiry

Background Service Service Packages Workflow Highlights FAQs Contact

Current CAR-T development faces major challenges including limited efficacy against solid tumors, severe cytokine release syndrome (CRS), and poor tissue penetration. Creative Biolabs' OMV & Exosome Boosted CAR-T Development Services are designed to overcome these barriers and accelerate your drug discovery process. Through advanced outer membrane vesicle engineering and high-purity exosomal isolation, we provide a cell-free or adjuvant-boosted platform that penetrates dense tumor stroma while maintaining therapeutic potency without systemic toxicity. Our approach offers superior safety, enhanced tumor infiltration, and streamlined bench-to-clinic transition, empowering you with high-efficacy candidates and reduced development risks.

Introduction

Engineered bacterial outer membrane vesicles (OMVs) and mammalian exosomes represent two powerful, cell-free nanoplatforms capable of modulating immune responses and delivering therapeutic payloads with high precision. Our services integrate these platforms to overcome solid tumor barriers, reversing immunosuppression, enabling antigen-independent tumor targeting, and minimizing cytokine release syndrome risk, thereby accelerating the next generation of safer and more effective cell therapies.

Fig.1 OMV and exosome-supported CAR-T development. (Creative Biolabs Original) Fig.1 OMV and exosome-enhanced CAR-T development.

OMV & Exosome Boosted CAR-T Development Services at Creative Biolabs

Creative Biolabs provides a streamlined approach to reduce risks in your immunotherapy pipeline. Our platform leverages EVs and OMVs, serving either as stand-alone CAR-exosome therapeutics or as microenvironment-remodeling boosters. These nanoscale delivery vehicles help your program cross the blood-brain barrier and counteract immunosuppressive cues that commonly drive CAR-T cell dysfunction.

Service Packages

OMV Engineering Services for CAR-T Infiltration

We engineer OMVs to functionally remodel the tumor stroma and promote CAR-T cell infiltration into solid tumors. These engineered OMVs carry chemoattractants and matrix-degrading enzymes, enabling CAR-T cells to overcome physical barriers and reach previously inaccessible tumor sites. This service is particularly valuable for treating desmoplastic or highly fibrotic solid tumors where poor infiltration limits therapeutic response.

Learn More →

Exosome Engineering Services for CAR-T Support (Mammalian-Derived)

Our mammalian exosome platform provides a biocompatible support system to sustain CAR-T cell activity within the suppressive tumor microenvironment. These engineered exosomes deliver co-stimulatory signals and metabolic modulators that prevent CAR-T exhaustion and promote long-term persistence.

Learn More →

Cargo Loading & Formulation for CAR-T Potentiation

We offer customized cargo loading and formulation solutions to equip OMV and exosome carriers with immunomodulatory or cytotoxic payloads that amplify CAR-T function. Small molecules, nucleic acids, or proteins can be efficiently encapsulated or surface-displayed to create synergistic effector systems. Our service enables precise control over release kinetics and targeting, facilitating next-generation CAR-T combination strategies with improved safety and potency.

Learn More →

Biological Validation & Safety of CAR-T Synergistic Systems

Our validation platform assesses both the efficacy and safety of OMV/exosome-CAR-T synergistic systems using relevant in vitro and in vivo models. We evaluate key parameters such as tumor clearance, cytokine profiles, off-target effects, and systemic toxicity to ensure regulatory readiness.

Learn More →

Our Service Process

Required Starting Materials:

The scFv/binder sequence for the target antigen.
Specific parameters regarding the desired carrier.

Key Steps:

Workflow of OMV & exosome boosted CAR-T development services at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables: You will receive a full Technical Validation Report, covering NTA-based size distribution, high-resolution imaging, and detailed pharmacokinetic data.

Key Advantages

Antigen-Independent Tumor Targeting: By engineering OMVs to install an artificial "synthetic marker" onto cancer cells, this approach overcomes tumor heterogeneity and enables CAR-T cells to recognize and eliminate antigen-negative or antigen-variable tumors.
Fully Customized Cargo Integration: We tailor each vesicle platform to your target antigens and incorporate specialized payloads, enabling precise modulation of the tumor microenvironment for enhanced CAR-T activity.

FAQs

Q1: Can you offer tailored engineering services for OMV development?

A1: Yes. Our platform supports complete customization, ranging from the selection of bacterial strains to the design and surface display of chimeric receptors, all precisely aligned with your target antigen and therapeutic context.

Q2: How does this platform affect the risk of CRS?

A2: Unlike live T cell therapies that undergo rapid in vivo expansion and activation-induced cytokine bursts, our exosome-based approach is cell-free and biologically contained. As a result, the potential for triggering severe CRS is extremely low, offering a substantially improved safety profile for clinical applications.

Why Choose Us

Our platform uniquely integrates engineered bacterial OMV and cell-free exosome technologies to overcome key CAR-T limitations in solid tumors. We enable simultaneous reversal of immunosuppression, antigen-independent tumor targeting, and minimal CRS risk.

How to contact us?

Ready to overcome CAR-T resistance in solid tumors? Partner with our experts to accelerate your next-generation cell therapy project. Request a quote, discuss custom OMV engineering, or schedule a confidential scientific consultation today.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.